Literature DB >> 10331086

Cyclins and cell cycle checkpoints.

D G Johnson1, C L Walker.   

Abstract

The eucaryotic cell cycle is regulated by the periodic synthesis and destruction of cyclins that associate with and activate cyclin-dependent kinases. Cyclin-dependent kinase inhibitors, such as p21 and p16, also play important roles in cell cycle control by coordinating internal and external signals and impeding proliferation at several key checkpoints. Understanding how these proteins interact to regulate the cell cycle has become increasingly important to researchers and clinicians with the discovery that many of the genes that encode cell cycle regulatory activities are targets for alterations that underlie the development of cancer. Several therapeutic agents, such as DNA-damaging drugs, microtubule inhibitors, antimetabolites, and topoisomerase inhibitors, take advantage of this disruption in normal cell cycle regulation to target checkpoint controls and ultimately induce growth arrest or apoptosis of neoplastic cells. Other therapeutic drugs being developed, such as UCN-01, specifically inhibit cell cycle regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331086     DOI: 10.1146/annurev.pharmtox.39.1.295

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  193 in total

1.  HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation.

Authors:  W Wang; M C Caldwell; S Lin; H Furneaux; M Gorospe
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

2.  Nitric oxide inhibits irreversibly P815 cell proliferation: involvement of potassium channels.

Authors:  R S A Costa; J Assreuy
Journal:  Cell Prolif       Date:  2002-12       Impact factor: 6.831

3.  Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene.

Authors:  Shashikiran Donthamsetty; Vishakha S Bhave; Corrine S Kliment; William C Bowen; Wendy M Mars; Aaron W Bell; Rachel E Stewart; Anne Orr; Chuanyue Wu; George K Michalopoulos
Journal:  Hepatology       Date:  2011-01-06       Impact factor: 17.425

4.  A translocator protein ligand PK11195 shows antigrowth activity in human choriocarcinoma cells.

Authors:  Noriyuki Takai; Naoko Kira; Terukazu Ishii; Toshie Yoshida; Masakazu Nishida; Yoshihiro Nishida; Kaei Nasu; Masayuki Takano; Haruna Midori; Satoko Koga; Hisashi Narahara
Journal:  Tumour Biol       Date:  2012-04-20

Review 5.  Virus manipulation of cell cycle.

Authors:  R Nascimento; H Costa; R M E Parkhouse
Journal:  Protoplasma       Date:  2011-10-11       Impact factor: 3.356

6.  ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer.

Authors:  Ainara Ruiz de Sabando; Chao Wang; Yuanjun He; Mónica García-Barros; Julie Kim; Kenneth R Shroyer; Thomas D Bannister; Vincent W Yang; Agnieszka B Bialkowska
Journal:  Mol Cancer Ther       Date:  2015-11-30       Impact factor: 6.261

7.  IL-39 acts as a friend to pancreatic cancer.

Authors:  Alicia A Manning; Lei Zhao; Ziwen Zhu; Huaping Xiao; Chase G Redington; Vivi A Ding; Theodore Stewart-Hester; Qian Bai; Jacob Dunlap; Mark R Wakefield; Yujiang Fang
Journal:  Med Oncol       Date:  2018-12-01       Impact factor: 3.064

8.  Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death.

Authors:  J Katchanov; C Harms; K Gertz; L Hauck; C Waeber; L Hirt; J Priller; R von Harsdorf; W Bruck; H Hortnagl; U Dirnagl; P G Bhide; M Endres
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

9.  The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer.

Authors:  Vivi A Ding; Ziwen Zhu; Timothy A Steele; Mark R Wakefield; Huaping Xiao; Dean Balabanov; Yujiang Fang
Journal:  Med Oncol       Date:  2017-12-05       Impact factor: 3.064

10.  Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.

Authors:  Yong Yang; Peng Zhang; Yanfeng Zhao; Jie Yang; Gening Jiang; Jie Fan
Journal:  Cancer Biol Ther       Date:  2015-10-22       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.